Denifanstat for moderate‐to‐severe acne: A Phase 2, randomized, double‐blind, placebo‐controlled trial
Journal of the European Academy of Dermatology and Venereology · 2026
DOI: 10.1111/jdv.70119 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2026. Verfasst von Qinyi Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Acne Vulgaris. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Ascletis BioScience Co., Ltd..
Abstract (Originalsprache)
Background
Acne vulgaris is a common chronic inflammatory skin disease with largely unmet treatment needs. Patients and Methods This was a multi‐centre, randomized, double‐blind, placebo‐controlled, dose‐escalation Phase 2 trial ( Clinicaltrials.gov ID: NCT05104125) to evaluate the safety, tolerability and efficacy of denifanstat, a first‐in‐class fatty acid synthase inhibitor, in patients with moderate‐to‐severe acne vulgaris. Denifanstat was administered orally at 25 ( n = 45), 50 ( n = 44), 75 ( n = 45) mg or placebo ( n = 45) once daily after dinner for 12 weeks.
Results
Denifanstat was generally well‐tolerated. Study drug‐related TEAEs were 48.9% (22/45), 47.7% (21/44), 62.2% (28/45) and 48.9% (22/45) in the denifanstat 25, 50 and 75 mg and placebo groups, respectively. The most common TEAEs were dry eye, dry skin, urine protein positive, skin peeling and conjunctivitis (Grade 1 to 2). No serious drug‐related TEAEs occurred. At Week 12, denifanstat demonstrated significantly greater median reductions in total lesion counts versus placebo (25 mg: −53.2% [Q1–Q3: −62.5% to −37.6%]; 50 mg: −61.3% [−78.2% to −29.1%]; 75 mg: −53.1% [−62.4% to −39.2%] vs. placebo: −34.2% [−53.0% to −18.4%]; all p < 0.05). The proportion of participants achieving a ≥ 2‐grade reduction in Investigator's Global Assessment (IGA) for denifanstat 25, 50 and 75 mg and placebo was 31.1% (14/45), 31.8% (14/44), 22.2% (10/45) and 15.6% (7/45), respectively. The difference among the four groups was not significant ( p = 0.336).
Conclusions
Denifanstat 50 mg once daily for 12 weeks was generally well tolerated and showed potential to reduce total lesion counts in moderate‐to‐severe acne vulgaris. Larger and longer term studies are needed to confirm efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
- The First People's Hospital of NanYang, Nanyang, Henan Province, China.
- Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China.
- First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China.
- Ningbo No. 2 Hospital, Ningbo, Zhejiang Province, China.
ORCID-Profile: Qinyi Chen, Yan Lu, Ying Gao, Leihong Xiang
Förderung
- Ascletis BioScience Co., Ltd.
Zitieren
APA
Chen, Q., Chen, R., Wu, L., Xu, A., He, L., Wang, J., Lu, Y., Xiao, R., Liu, L., Feng, Y., Zhang, C., Dai, X., Gao, Y., Yan, Y., Wu, J. J., & Xiang, L. (2026). Denifanstat for moderate‐to‐severe acne: A Phase 2, randomized, double‐blind, placebo‐controlled trial. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70119
Vancouver
Chen Q, Chen R, Wu L, Xu A, He L, Wang J, et al. Denifanstat for moderate‐to‐severe acne: A Phase 2, randomized, double‐blind, placebo‐controlled trial. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70119
BibTeX
@article{Chen2026,
author = {Chen, Qinyi and Chen, Rixin and Wu, Liming and Xu, Ai'e and He, Li and Wang, Jinyan and Lu, Yan and Xiao, Rong and Liu, Lunfei and Feng, Yanyan and Zhang, Chunlei and Dai, Xunyi and Gao, Ying and Yan, Yuemei and Wu, Jinzi J and Xiang, Leihong},
title = {Denifanstat for moderate‐to‐severe acne: A Phase 2, randomized, double‐blind, placebo‐controlled trial},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
doi = {10.1111/jdv.70119}
}
EUVIMED